



DFV

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMS 9551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

7

Application Number

10/526,429

Filing Date

February 28, 2005

First Named Inventor

ROMMENS, Johanna M.

Art Unit

TBD

Examiner Name

TBD

Attorney Docket Number

8092-002-US

ENCLOSURES

(Check all that apply)

- ☐ Fee Transmittal Form
☐ Fee Attached
☐ Amendment/Reply
☐ After Final
☐ Affidavits/declaration(s)
☐ Extension of Time Request
☐ Express Abandonment Request
☒ Information Disclosure Statement

☐ Certified Copy of Priority Document(s)
☐ Reply to Missing Parts/ Incomplete Application
☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Drawing(s)
☐ Licensing-related Papers

☐ Petition
☐ Petition to Convert to a Provisional Application
☐ Power of Attorney, Revocation
☐ Change of Correspondence Address
☐ Terminal Disclaimer
☐ Request for Refund
☐ CD, Number of CD(s) _____
☐ Landscape Table on CD

- ☐ After Allowance Communication to TC

☐ Appeal Communication to Board of Appeals and Interferences

☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☐ Other Enclosure(s) (please identify below):
Self Addressed Pre-Paid Stamped Postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	CATALYST LAW GROUP, APC		
Signature			
Printed name	David M. Kahn, J.D.		
Date	February 9, 2006	Reg. No.	53,150

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Christina Dueñas	Date	February 9, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT
8092-002-US

February 9, 2006

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Mail Stop: Information Disclosure Statement, P. O. Box 1450, Alexandria, VA 22313-1450.

Christina Dueñas

Name of Person Mailing Paper

Signature of Person Mailing Paper

February 9, 2006

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Examiner: TBA
)	
Rommens, Johanna M., et al.)	Group Art Unit: TBA
)	
Serial No.: 10/526,429)	Docket No.: 8092-002-US
)	
Filed: February 28, 2005)	Date Mailed: February 9, 2006
)	
For: DIAGNOSIS OF SHWACHMAN-)	
DIAMOND SYNDROME)	
)	

INFORMATION DISCLOSURE STATEMENT

Mail Stop: Information Disclosure Statement
Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

This document is an Information Disclosure Statement to the above-cited patent application and filed pursuant to 37 C.F.R. § 1.97(b)(3). Therefore, no fee is believed to be due.

Attached is form 1449A/PTO listing documents believed relevant to the subject application. The submission of this document is not intended, nor should it be construed, to constitute an admission that any patent, patent application, article, or other information referred to herein is "prior art" unless specifically designated as such. In fact, applicants submit that these documents do not affect the patentability of the subject invention. In accordance with 37 C.F.R. § 1.97(g), the filing of this information shall not be construed to represent that a search has been made or that no other material information may exist. Neither should its submission be construed to indicate that a thorough search should not be conducted by the Examiner.

It is respectfully requested that the listing of documents in the attached forms be: (1) fully considered by the Patent and Trademark Office during the prosecution of this application; and (2) represented on any patent which may issue on the application. Applicant respectfully requests that the copies of the forms 1449A/PTO, be considered and initialed by the Examiner, be returned with the next communication pursuant to the §609 of the Manual of Patent Examining Procedures (MPEP).

The order of the documents listed in the attached forms is to be accorded no particular import, as the order thereof is completely fortuitous. Additionally, the documents are not necessarily analogous art. A copy of each article document listed in the attached form is enclosed.


It is believed that this disclosure complies with the requirements as set forth under 37 C.F.R. § 1.56, § 1.97, and § 1.98 and §707.05(b) of the MPEP. If for some reason the Examiner considers otherwise, it is respectfully requested that the undersigned be telephoned at (858) 450-0099 so that any deficiencies can be remedied.

It is further believed that this Information Disclosure Statement is being submitted before the mailing of an Office Action on the merits. Accordingly, no fee is believed to be due

under 37 C.F.R. § 197(b)(3). If an Office Action on the merits has in fact been mailed, authorization is hereby given to charge the required fee of \$180.00 under 37 C.F.R. § 1.97(c)(2) and 1.17(p) to Deposit Account No. 502235.

Respectfully submitted,

Date: 2/9/06



David M. Kohn, J.D.
Reg. No. 53,150

CATALYST LAW GROUP, APC
9710 Scranton Road, Suite 170
San Diego, California 92121
(858) 450-0099
(858) 450-9834 (Fax)

Sheet 1 of 3



Application Number	10/526,429
Filing Date	February 28, 2005
First Named Inventor	ROMMENS, Johanna M.
Group Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	8092-002-US

[illegible]

Examiner Initials*	Cite No.	U.S. Serial No.	Name of Applicant of Cited Document	Date of Filing of Cited Document MM-DD-YYYY
		US-		
		US-		
		US-		
		US-		
		US-		

[illegible]

Examiner Initials*	Cite No.	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
/D.T./	2.	SHWACHMAN, H., Diamond, L.K. & Khaw, K., (1964), "The Syndrome of Pancreatic Insufficiency and Bone Marrow Dysfunction", <i>J. Pediatr.</i> v. 65, pp. 645-663.	
/D.T./	3.	GINZBERG, H. et al., (1999), "Shwachman Syndrome: Phenotypic Manifestations of Sibling Sets and Isolated Cases in a Large Patient Cohort are Similar", <i>J. Pediatr.</i> v. 135, pp. 81-88.	

05/27/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

**Complete if Known**

Application Number	10/526,429
Filing Date	February 28, 2005
First Named Inventor	ROMMENS, Johanna M.
Group Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	8092-002-US

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
/D.T./	4.	GINZBERG, H. et al., (2000), "Segregation analysis in Shwachman-Diamond Syndrome: Evidence for Recessive Inheritance", Am. J. Hum. Genet. v. 66, pp. 1413-1416.	
	5.	GOOBIE, S. et al., (2001), "Shwachman-Diamond syndrome with exocrine pancreatic dysfunction and bone marrow failure maps to the centromeric region of chromosome 7", Am. J. Hum. Genet. v. 68, pp. 1048-1054.	
	6.	POPOVIC, M. et al., (2002), "Fine mapping of the locus for Shwachman-Diamond syndrome at 7q11, identification of shared disease haplotypes, and exclusion of TPST1 as a candidate gene", Eur. J. Hum. Genet. v. 10, pp. 250-8.	
	7.	KOONIN, E.V., Wolf, Y.I. & Aravind, L. (2001), "Prediction of the archaeal exosome and its connections with the proteasome and the translation and transcription machineries by a comparative-genomic approach". Genome Res. 11, 240-252.	
	8.	ROESLER, J. et al., (2000), "Recombination events between the p47-phox gene and its highly homologous pseudogenes are the main cause of autosomal recessive chronic granulomatous disease". Blood, v. 15, pp. 2150-2156.	
	9.	STRACHAN T., (1994), "Molecular pathology of 21-hydroxylase deficiency", J. Inherit. Metab. Dis., v. 17, pp. 430-41	
	10.	NEW, M.I., (1994), "Steroid 21-hydroxylase deficiency (congenital adrenal hyperplasia)", Am. J. Med., v. 98(1A), pp. 1A-2S-1A-8S.	
	11.	BEUTLER, E., (1993), "Gaucher disease as a paradigm of current issues regarding single gene mutations of humans", Proc. Natl. Acad. Sci. USA, v. 90, pp. 5384-5390.	
	12.	EIKENBOOM, J.C., et al., (1994), "Multiple substitutions in the von Willebrand factor gene that mimic the pseudogene sequence", Proc. Natl. Acad. Sci. USA, v. 91, pp. 2221-2224.	
	13.	WATNICK, T. J., et al., (1998), "Gene conversion is a likely cause of mutation in PKD1", Hum. Mol. Genet. v. 7, pp. 1239-1243.	
	14.	CHEN, J. M. and FEREC, C., (2000), "Molecular basis of hereditary pancreatitis", Eur. J. Hum. Genet. v. 8, pp. 473-479.	
	15.	CHEN, J. M., et al., (2000), "A CGC-CAT gene conversion-like event resulting in the R122H mutation in the cationic trypsinogen gene and its implication in the genotyping of pancreatitis", J. Med. Genet., v. 37, E36.	
	16.	CAI, L. et al., (2001), "A novel Q378X mutation exists in the transmembrane transporter protein ABCB6 and its pseudogene: implications for mutation analysis in pseudoxanthoma elasticum", J. Mol. Med., v. 79, pp. 536-546.	
	17.	BUNGE, S., et al., (1998), "Homologous nonallelic recombinations between the iduronate-sulfatase gene and pseudogene cause various intragenic deletions and inversions in patients with mucopolysaccharidosis type II", Eur. J. Hum. Genet., v. 6, pp. 492-500.	
	18.	HAHNEN, E., et al., (1996), "Hybrid survival motor neuron genes in patients with autosomal recessive spinal muscular atrophy: new insights into molecular mechanisms responsible for the disease", Am. J. Hum. Genet., v. 59, pp. 1057-1065.	
	19.	CAMPBELL, L., et al., (1997), "Genomic variation and gene conversion in spinal muscular atrophy: Implications for disease process and clinical phenotype", Am. J. Hum. Genet., v. 61, pp. 40-50.	
	20.	WIRTH, B., et al., (1997), "De novo rearrangements found in 2% of index patients with spinal muscular atrophy: Mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling", Am. J. Hum. Genet., v. 61, pp. 1102-1111.	
	21.	ZHU, H., et al., (2001), "Global analysis of protein activities using proteome chips", Science., v. 293, pp. 2101-2105.	
	22.	BATEMAN, A., et al., (2002), "The Pfam Protein Families Database", Nucl. Acids Res. 30(1):276-280.	

Examiner Signature

/David Thomas/

Date Considered


05/27/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

**Complete if Known**

Application Number	10/526,429
Filing Date	February 28, 2005
First Named Inventor	ROMMENS, Johanna M.
Group Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	8092-002-US

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
/D.T./	23.	WINZELER, E. A., et al., (1999), "Functional characterization of the <i>S. cerevisiae</i> genome by gene deletion and parallel analysis", <i>Science</i> , v. 285, pp. 901-906.	
	24.	WU, L. F. et al., (2002), "Large-scale prediction of <i>Saccharomyces cerevisiae</i> gene function using overlapping transcriptional clusters", <i>Nat. Genet.</i> , v. 31, pp. 255-265.	
	25.	MILLER, S.A., DYKES, D.D., & POLESKY, H.F. (1988), "A simple salting out procedure for extracting DNA from human nucleated cells", <i>Nucleic Acids Res.</i> v. 16, 1215.	
	26.	MACDONALD, R.J., et al., (1987) "Isolation of RNA using guanidinium salts", <i>Meth. Enzymol.</i> 152, 219-234.	
	27.	BENSON, D.A., et al., (2002), <i>GenBank</i> . <i>Nucleic Acids Res.</i> v. 30, 17-20.	
	28.	HUBBARD, T., et al., (2002), "The Ensembl genome database project", <i>Nucleic Acids Res.</i> 30, 38-41.	
	29.	SCHWARTZ, S., et al. (2000), "PipMaker - A Web Server for Aligning Two Genomic DNA Sequences", <i>Genome Res.</i> v. 10, 577-586.	
	34.	ROZEN, S. and SKALETSKY, H.J., (2000), "Primer3 on the WWW for general users and for biologist programmers", In: Krawetz, S., and S. Misener. <i>Bioinformatics Methods and Protocols: Methods in Molecular Biology</i> , Humana Press, Totowa, NJ.	
	31.	ISOGAI, T., et al. (2000), "NEDO human cDNA sequencing project", <i>Genbank</i> Accession no. AK001779, Abstract XP002268960.	
	37.	POPOVIC, M., et al., (2000), "Refined mapping of the Shwachman-Diamond syndrome locus at 7p12-q11." <i>Amer. J. Human Genetics</i> v. 67, pp. 321: XP002268959: Abstract.	
	39.	BOOCOOCK, G., et al., (2003), "Mutations in SBDS are associated with Shwachman-Diamond syndrome" <i>Nature Genetics</i> , v. 33, pp. 97-101.	
	34.	PRADES, C., et al., (2002), "The human ATP binding cassette gene ABCA13, located on chromosome 7p12.3, encodes a 5058 amino acid protein with an extracellular domain encoded in part by a 4.8-kb conserved exon", <i>Cytogenetic and Genome Research</i> v. 98(2-3):160-168.	
	35.	SMITH, A., et al., (2002), "Intermittent 20q- and consistent i(7q) in a patient with Shwachman-Diamond syndrome," <i>Pediatr. Hematol. Oncol.</i> v. 19(7):525-528.	
	36.	ELGHETANY, M.T. and ALTER, B.P., (2002) "p53 Protein Overexpression in Bone Marrow biopsies of patients with Shwachman-Diamond syndrome has a prevalence similar to that of patients with refractory anemia", <i>Arch. Pathol. Lab. Med.</i> v. 126(4):452-455.	
	37.	JELIC, T.M, et al., (2001) "Expression of CD5 on Hematogones in a 7-year-old girl with Shwachman-Diamond Syndrome", <i>Pediatr. Develop. Pathol.</i> v. 4(5):505-511.	
	38.	SPIRITO, F.R., et al., (2000) "Cytogenetic characterization of acute myeloid leukemia in Shwachman's syndrome, A case report, <i>Haematologica</i> v. 85(11):1207-1210.	
	39.	DALE, D.C., et al., (2000) "Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia", <i>Blood</i> , v. 96(7):2317-2322.	
	40.	SOKOLIC, R.A., et al., (1999) "Discordant detection of monosomy 7 by GTG-banding and FISH in a patient with Shwachman-Diamond syndrome without evidence of myelodysplastic syndrome or acute myelogenous leukemia", <i>Cancer Genetics & Cytogenetics</i> , 115(2):106-13.	

Examiner Signature	/David Thomas/	Date Considered	05/27/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.